<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700841</url>
  </required_header>
  <id_info>
    <org_study_id>669-19</org_study_id>
    <secondary_id>NCI-2015-00743</secondary_id>
    <nct_id>NCT02700841</nct_id>
  </id_info>
  <brief_title>Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation</brief_title>
  <official_title>A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution
      following transplantation of an autologous mobilized graft product to reconstitution
      following transplantation of a mobilized graft product followed by an autologous lymphocyte
      infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines
      pre and post-transplant. The primary end point will be tetanus vaccine immune responses
      post-transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

        1. To compare the cellular and humoral vaccine response post-transplant between the two
           arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays

        2. To determine the feasibility and safety of this approach

      SECONDARY OBJECTIVES:

        1. To compare post-transplant recovery of innate and adaptive immune cells (CD8, CD4, CD19,
           NK, γδ T-cells), in addition to T-cell phenotype markers between the two arms.

        2. To compare post-transplant recovery of T-regs and MDSCs between the two arms.

        3. To compare progression free survival (PFS) at 2 years post-transplant
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Protocol is being modified and moved to another institution
  </why_stopped>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of safely treated patients (feasibility and safety)</measure>
    <time_frame>Baseline to 180 days post-transplant</time_frame>
    <description>Determine safety of outcomes by CTCAE version 5.0 tool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Kaplan Meier method, Logrank test, and Cox model will be employed to investigate the effect of ALC, AMC, and immune cells on survival post AHSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation--CD34 HSCT</intervention_name>
    <description>Undergo autologous CD34 HSCT</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <other_name>PBPC Transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation--AHSCT</intervention_name>
    <description>Undergo AHSCT</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T Cell-Depleted Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous CD34 HSCT</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus Toxoid Vaccine</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <other_name>Tetanus Toxoid</other_name>
    <other_name>TT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 19 years to 70 years old at time of study entry (consent)

          2. Diagnosis of Multiple Myeloma as per updated International Myeloma Working Group
             (IMWG) criteria .

          3. Must have measurable disease defined as: for secretory MM, serum monoclonal protein
             ≥1.0 g/dL, urine monoclonal protein ≥200 mg/24 hrs, and involved free light chain ≥ 10
             mg/dL; or in case of non-secretory MM, bone marrow plasma cell percentage ≥30%.

          4. Must have standard risk myeloma (see exclusion criterion 4).

          5. Must have received bortezomib, lenalidomide and dexamethasone (VRd) as a form of
             induction therapy pre-AHSCT (use of cyclophosphamide, bortezomib and dexamethasone may
             be allowed for up to 2 weekly doses before initiation of VRd induction, if necessary
             clinically for cytoreduction)

          6. Able to understand and sign a consent form.

          7. Creatinine clearance equal or &gt; 60 ml/min (calculated)

          8. Ejection fraction equal or &gt; 50% before admission for transplant as per institutional
             standards. Patients with coronary heart disease (recent myocardial infarctions,
             angina, cardiac stent, or bypass surgery in the last 6 months or arrhythmia) need to
             be cleared by cardiology as per institutional BMT standards.

          9. Serum bilirubin, ALT, AST less than 3 X upper limit of normal

         10. FVC, FEV1 or DLCO &gt;50% predicted before admission for transplant as per institutional
             standards. Patients on home oxygen are not allowed on the protocol.

         11. No more than 6 months of pre-transplant MM chemotherapy is allowed (from the date of
             the start of the induction therapy).

         12. KPS ≥ 70%or ECOG 0-2.

         13. Must be eligible to receive Melphalan dose of 200mg/m2

         14. A female of child-bearing potential, must have two negative urine pregnancy test
             results within 10 to 14 days prior to starting the first dose of vaccine
             pre-transplant as a way of ensuring safe transplant planning.

        Exclusion Criteria:

          1. Participation in another clinical study with an investigational product during the
             last 28 days.

          2. Prior stem cell transplant (either autologous or allogeneic)

          3. Creatinine clearance &lt; 60 ml/min (calculated)

          4. High risk MM defined as those with the following disease, fluorescence in situ
             hybridization and/or cytogenetic features: del17p, del1p with 1q gain, t(4;14),
             t(14;16), t(14;20), &gt;1 cytogenetic abnormality on karyotype, hypodiploid, plasma cell
             leukemia (primary or secondary), or subjects who failed to achieve ≥PR to induction
             therapy (i.e. VRd) and required salvage induction prior to AHSCT.

          5. Documented central nervous system or extramedullary disease.

          6. Significant organ dysfunction deemed to carry inappropriate risk for AHSCT.

          7. Intention or plans for cyclophosphamide mobilization.

          8. Known allergic reactions after previous tetanus diphtheria vaccination or had a
             condition of Guillain Barre Syndrome (GBS)

          9. Known active hepatitis B, C or HIV infections on initial assessment.

         10. Enrollment on any other transplant related protocols.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhamed Baljevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Muhamed Baljevic, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

